跳转至内容
Merck
  • An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis.

An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis.

PloS one (2014-10-23)
Yu-Hua Chao, Han-Ping Wu, Kang-Hsi Wu, Yi-Giien Tsai, Ching-Tien Peng, Kuan-Chia Lin, Wan-Ru Chao, Maw-Sheng Lee, Yun-Ching Fu
摘要

Sepsis remains an important cause of death worldwide, and vigorous immune responses during sepsis could be beneficial for bacterial clearance but at the price of collateral damage to self tissues. Mesenchymal stem cells (MSCs) have been found to modulate the immune system and attenuate sepsis. In the present study, MSCs derived from bone marrow and umbilical cord were used and compared. With a cecal ligation and puncture (CLP) model, the mechanisms of MSC-mediated immunoregulation during sepsis were studied by determining the changes of circulating inflammation-associated cytokine profiles and peripheral blood mononuclear cells 18 hours after CLP-induced sepsis. In vitro, bone marrow-derived MSCs (BMMSCs) and umbilical cord-derived MSCs (UCMSCs) showed a similar morphology and surface marker expression. UCMSCs had stronger potential for osteogenesis but lower for adipogenesis than BMMSCs. Compared with rats receiving PBS only after CLP, the percentage of circulating CD3+CD4+CD25+ regulatory T (Treg) cells and the ratio of Treg cells/T cells were elevated significantly in rats receiving MSCs. Further experiment regarding Treg cell function demonstrated that the immunosuppressive capacity of Treg cells from rats with CLP-induced sepsis was decreased, but could be restored by administration of MSCs. Compared with rats receiving PBS only after CLP, serum levels of interleukin-6 and tumor necrosis factor-α were significantly lower in rats receiving MSCs after CLP. There were no differences between BMMSCs and UCMSCs. In summary, this work provides the first in vivo evidence that administering BMMSCs or UCMSCs to rats with CLP-induced sepsis could increase circulating CD3+CD4+CD25+ Treg cells and Treg cells/T cells ratio, enhance Treg cell suppressive function, and decrease serum levels of interleukin-6 and tumor necrosis factor-α, suggesting the immunomodulatory association of Treg cells and MSCs during sepsis.

材料
货号
品牌
产品描述

Sigma-Aldrich
地塞米松, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
3-异丁基-1-甲基黄嘌呤, ≥99% (HPLC), powder
Sigma-Aldrich
3-异丁基-1-甲基黄嘌呤, BioUltra, ≥99%
Sigma-Aldrich
地塞米松, ≥98% (HPLC), powder
Sigma-Aldrich
吲哚美辛, 98.5-100.5% (in accordance with EP)
Sigma-Aldrich
5(6)-羧基二乙酸荧光素 N-琥珀酰亚胺酯, BioReagent, suitable for fluorescence, ≥90% (HPLC)
Sigma-Aldrich
地塞米松, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
USP
地塞米松, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
吲哚美辛, meets USP testing specifications
Sigma-Aldrich
地塞米松, meets USP testing specifications
Supelco
地塞米松, Pharmaceutical Secondary Standard; Certified Reference Material
USP
吲哚美辛, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
5-Carboxy-fluorescein diacetate N-succinimidyl ester, for fluorescence, ≥95.0% (HPLC)
Supelco
吲哚美辛, Pharmaceutical Secondary Standard; Certified Reference Material
吲哚美辛, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
地塞米松, tested according to Ph. Eur.
Supelco
地塞米松, VETRANAL®, analytical standard
地塞米松, European Pharmacopoeia (EP) Reference Standard
地塞米松, British Pharmacopoeia (BP) Assay Standard
地塞米松, European Pharmacopoeia (EP) Reference Standard
地塞米松, European Pharmacopoeia (EP) Reference Standard